 |
 |
|
15 January 2002 | Volume 136 Issue 2 | Pages 157-160
This statement summarizes the recommendation of the third U.S. Preventive Services Task Force (USPSTF) for aspirin for the primary prevention of cardiovascular events, as well as the supporting scientific evidence. The complete information on which this statement is based, including evidence tables and references, can be found in a companion article in this issue. Copies of this document, the summary of the evidence, and the systematic evidence review can be obtained through the USPSTF Web site (http://www.ahrq.gov/clinic/uspstfix.htm) and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (800-358-9295).
*For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.
Author and Article Information
From the U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality, Rockville, Maryland.
Requests for Single Reprints: Reprints are available from the USPSTF Web site (http://www.ahrq.gov/clinic/uspstfix.htm) and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (800-358-9295). CLINICAL GUIDELINES
Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  American Diabetes Association Standards of Medical Care in Diabetes--2009 Diabetes Care, January 1, 2009; 32(Supplement_1): S13 - S61. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spring Health Decision Making: Lynchpin of Evidence-Based Practice Med Decis Making, November 1, 2008; 28(6): 866 - 874. [Abstract] [PDF]
|
|
|
|
|
|
I. B. Hirsch, S. E. Inzucchi, and M. S. Kirkman Standards of Medical Care in Diabetes--2008: Response to Dora, Kramer, and Canani Diabetes Care, May 1, 2008; 31(5): e45 - e45. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono and B. Rocca Aspirin: Promise and Resistance in the New Millennium Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s25 - s32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2008 Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Glynn, P. M Ridker, S. Z. Goldhaber, and J. E. Buring Effect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism: A Randomized Trial Ann Intern Med, October 16, 2007; 147(8): 525 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ardoin, C. Sandborg, and L. Schanberg Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 618 - 626. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation Circulation, May 29, 2007; 115(21): 2689 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Cohen and P. J. Neumann What's More Dangerous, Your Aspirin Or Your Car? Thinking Rationally About Drug Risks (And Benefits) Health Aff., May 1, 2007; 26(3): 636 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Jacobs, M. J. Thun, E. B. Bain, C. Rodriguez, S. J. Henley, and E. E. Calle A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence J Natl Cancer Inst, April 18, 2007; 99(8): 608 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Rippe, T. J. Angelopoulos, and L. Zukley Lifestyle Medicine Strategies for Risk Factor Reduction, Prevention, and Treatment of Coronary Heart Disease: Part II American Journal of Lifestyle Medicine, March 1, 2007; 1(2): 79 - 90. [Abstract] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes--2007 Diabetes Care, January 1, 2007; 30(suppl_1): S4 - S41. [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Sequist, R. Marshall, S. Lampert, E. J. Buechler, and T. H. Lee Missed opportunities in the primary care management of early acute ischemic heart disease. Arch Intern Med, November 13, 2006; 166(20): 2237 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. O'Kennedy, L. Crosbie, S. Whelan, V. Luther, G. Horgan, J. I Broom, D. J Webb, and A. K Duttaroy Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. Am. J. Clinical Nutrition, September 1, 2006; 84(3): 561 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Hennekens, O. Sechenova, D. Hollar, and V. L. Serebruany Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 170 - 176. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Hur, A. T Chan, A. C Tramontano, and G S. Gazelle Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs Ann. Pharmacother., June 1, 2006; 40(6): 1052 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pignone, S. Earnshaw, J. A. Tice, and M. J. Pletcher Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med, March 7, 2006; 144(5): 326 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Berger, M. C. Roncaglioni, F. Avanzini, I. Pangrazzi, G. Tognoni, and D. L. Brown Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-analysis of Randomized Controlled Trials JAMA, January 18, 2006; 295(3): 306 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt, P. G. Steg, E. M. Ohman, A. T. Hirsch, Y. Ikeda, J.-L. Mas, S. Goto, C.-S. Liau, A. J. Richard, J. Rother, et al. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis JAMA, January 11, 2006; 295(2): 180 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Blann Antiplatelet therapy and the vascular tree Heart, January 1, 2006; 92(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes-2006 Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42. [Full Text] [PDF]
|
|
|
|
|
|
Prepared by: British Cardiac Society, British Hype JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart, December 1, 2005; 91(suppl_5): v1 - v52. [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Eikelboom Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis Evid. Based Med., October 1, 2005; 10(5): 136 - 136. [Full Text] [PDF]
|
|
|
|
|
|
J. W Eikelboom Low dose aspirin lowered stroke risk but not risks of MI or cardiovascular deaths in women Evid. Based Med., October 1, 2005; 10(5): 137 - 137. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chen Low-dose aspirin: Major benefits, minimal cost Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1357 - 1357. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Saseen ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1398 - 1405. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ridker, N. R. Cook, I-M. Lee, D. Gordon, J. M. Gaziano, J. E. Manson, C. H. Hennekens, and J. E. Buring A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women N. Engl. J. Med., March 31, 2005; 352(13): 1293 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hur, L. S Simon, and G S. Gazelle Analysis of Aspirin-Associated Risks in Healthy Individuals Ann. Pharmacother., January 1, 2005; 39(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American Diabetes Association Standards of Medical Care in Diabetes Diabetes Care, January 1, 2005; 28(suppl_1): S4 - S36. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Persell and D. W. Baker Aspirin Use Among Adults With Diabetes: Recent Trends and Emerging Sex Disparities Arch Intern Med, December 13, 2004; 164(22): 2492 - 2499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Cox, M. Frisse, A. Behm, and K. A. Fairman Over-the-Counter Pain Reliever and Aspirin Use Within a Sample of Long-term Cyclooxygenase 2 Users Arch Intern Med, June 14, 2004; 164(11): 1243 - 1246. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Howard and P. Delafontaine Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk J. Am. Coll. Cardiol., February 18, 2004; 43(4): 519 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hur, N. S. Nishioka, and G. S. Gazelle Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus J Natl Cancer Inst, February 18, 2004; 96(4): 316 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Chan, E. L. Giovannucci, E. S. Schernhammer, G. A. Colditz, D. J. Hunter, W. C. Willett, and C. S. Fuchs A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma Ann Intern Med, February 3, 2004; 140(3): 157 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Standards of Medical Care in Diabetes Diabetes Care, January 1, 2004; 27(90001): s15 - 35. [Full Text] [PDF]
|
|
|
|
|
|
Aspirin Therapy in Diabetes Diabetes Care, January 1, 2004; 27(90001): s72 - 73. [Full Text] [PDF]
|
|
|
|
|
|
M. Sacco, F. Pellegrini, M. C. Roncaglioni, F. Avanzini, G. Tognoni, and A. Nicolucci Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial Diabetes Care, December 1, 2003; 26(12): 3264 - 3272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Colwell Aspirin for Primary Prevention of Cardiovascular Events in Diabetes Diabetes Care, December 1, 2003; 26(12): 3349 - 3350. [Full Text] [PDF]
|
|
|
|
|
|
J. E Shaw Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk Evid. Based Med., November 1, 2003; 8(6): 178 - 179. [Full Text] [PDF]
|
|
|
|
|
|
J. E Shaw Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer Evid. Based Med., November 1, 2003; 8(6): 179 - 179. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Eidelman, P. R. Hebert, S. M. Weisman, and C. H. Hennekens An Update on Aspirin in the Primary Prevention of Cardiovascular Disease Arch Intern Med, September 22, 2003; 163(17): 2006 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Morrell Initiating antiplatelet therapy in diabetes: a PCO view The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 349 - 353. [Abstract] [PDF]
|
|
|
|
|
|
J. G. Canto and A. E. Iskandrian Major Risk Factors for Cardiovascular Disease: Debunking the "Only 50%" Myth JAMA, August 20, 2003; 290(7): 947 - 949. [Full Text] [PDF]
|
|
|
|
|
|
B. M.R. Spiegel, L. Targownik, G. S. Dulai, and I. M. Gralnek The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis Ann Intern Med, May 20, 2003; 138(10): 795 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Przyklenk and G. Heusch Late preconditioning against myocardial stunning: Does aspirin close the "second window" of endogenous cardioprotection? J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1195 - 1197. [Full Text] [PDF]
|
|
|
|
|
|
G. E. McLaughlin Aspirin for the Primary Prevention of Cardiovascular Events Ann Intern Med, October 1, 2002; 137(7): 622 - 623. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Pearson, S. N. Blair, S. R. Daniels, R. H. Eckel, J. M. Fair, S. P. Fortmann, B. A. Franklin, L. B. Goldstein, P. Greenland, S. M. Grundy, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases Circulation, July 16, 2002; 106(3): 388 - 391. [Full Text] [PDF]
|
|
|
|
|
|
M. Jain and M. Rosenberg Review: aspirin reduces CAD events in people with no history of cardiovascular disease, but it increases gastrointestinal bleeding Evid. Based Med., July 1, 2002; 7(4): 111 - 111. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Lauer Aspirin for Primary Prevention of Coronary Events N. Engl. J. Med., May 9, 2002; 346(19): 1468 - 1474. [Full Text] [PDF]
|
|
|
|
|
|
G. Lowe Review: Which patients with diabetes should receive which antiplatelet agents? The British Journal of Diabetes & Vascular Disease, May 1, 2002; 2(3): 157 - 160. [Abstract] [PDF]
|
|
|
|
 |
|
 Guidelines: Aspirin for Primary Prevention of Adverse Cardiovascular Events Journal Watch Cardiology, February 22, 2002; 2002(222): 1 - 1. [Full Text]
|
|
|
|
 |
|
 Aspirin for Primary Prevention: Trade-Off Between Bleeding and Prevention of Cardiovascular Events Journal Watch (General), February 1, 2002; 2002(201): 2 - 2. [Full Text]
|
|
Article
